Evidence map›Paper›PMID 25368604›Full record

ArticleFrontiers in endocrinology2014

Deletion of P58(IPK), the Cellular Inhibitor of the Protein Kinases PKR and PERK, Causes Bone Changes and Joint Degeneration in Mice.

Sophie J Gilbert, Lee B Meakin, Cleo S Bonnet, Mari A Nowell, Warren C Ladiges, John Morton, Victor C Duance, Deborah J Mason

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Curcumin Inhibits the PERK-eIF2Oxidative medicine and cellular longevity · 2019
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sophie J GilbertPathophysiology and Repair Division, Arthritis Research UK Biomechanics and Bioengineering Centre, School of Biosciences, Cardiff University , Cardiff , UK.
Lee B MeakinSchool of Veterinary Sciences, University of Bristol , Bristol , UK.
Cleo S BonnetPathophysiology and Repair Division, Arthritis Research UK Biomechanics and Bioengineering Centre, School of Biosciences, Cardiff University , Cardiff , UK.
Mari A NowellSection of Inflammation, Skin and Joint Disease, Institute of Infection and Immunity, School of Medicine, Cardiff University , Cardiff , UK.
Warren C LadigesDepartment of Comparative Medicine, School of Medicine, University of Washington , Seattle, WA , USA.
John MortonDepartment of Comparative Medicine, School of Medicine, University of Washington , Seattle, WA , USA.
Victor C DuancePathophysiology and Repair Division, Arthritis Research UK Biomechanics and Bioengineering Centre, School of Biosciences, Cardiff University , Cardiff , UK.
Deborah J MasonPathophysiology and Repair Division, Arthritis Research UK Biomechanics and Bioengineering Centre, School of Biosciences, Cardiff University , Cardiff , UK.
University of Washington · USUniversity of Bristol · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

objectiveProtein kinase-like endoplasmic reticulum kinase (PERK) and protein kinase R (PKR) are implicated in endoplasmic reticulum stress-induced arthritis and pro-inflammatory cytokine-mediated cartilage degradation in vitro, respectively. We determined whether knockout of the cellular inhibitor of PERK and PKR, P58(IPK) causes joint degeneration in vivo and whether these molecules are activated in human osteoarthritis (OA). MATERIALS AND

methodsSections of knee joints from P58(IPK)-null and wild-type mice aged 12-13 and 23-25 months were stained with toluidine blue and scored for degeneration using the osteoarthritis research society international (OARSI) system. Bone changes were assessed by radiology and high-resolution micro-computed tomography of hind limbs. Sections from the medial tibial plateaus of two human knees, removed in total knee replacement surgery for OA, were immunolabelled for phosphorylated PERK and PKR and P58(IPK).

resultsKnockout mice exhibited narrower tibiae (p = 0.0031) and smaller epiphyses in tibiae (p = 0.0004) and femora (p = 0.0214). Older knockout mice had reduced total volume inside the femoral periosteal envelope (p = 0.023), reduced tibial (p = 0.03), and femoral (p = 0.0012) bone volumes (BV) and reduced femoral BV fraction (p = 0.025). Compared with wild-types, younger P58(IPK)-null mice had increased OARSI scores in medial femoral condyles (p = 0.035). Thirty four percent of null mice displayed severe joint degeneration with complete articular cartilage loss from the medial compartment and heterotopic chondro-osseous tissue in the medial joint capsule. Phosphorylated PERK and PKR were localized throughout human osteoarthritic tibial plateaus but, in particular, in areas exhibiting the most degeneration. There was limited expression of P58(IPK).

conclusionThis study is the first to reveal a critical role for P58(IPK) in maintaining joint integrity in vivo, implicating the PKR and PERK stress signaling pathways in bony changes underlying the pathogenesis of joint degeneration.

Indexed as

articular cartilageboneosteoarthritisP58IPKPERKPKR

Identifiers

PMID25368604
PMCPMC4201149
OpenAlexW2021928504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.